The use of renin-angiotensin system (RAS) inhibitors is alleged to cause a more severe course of coronavirus disease 2019 (COVID-19).

We systematically reviewed the published studies to assess the association of RAS inhibitors with mortality as well as disease severity in COVID-19 patients.

The meta-analyses favoured the continued use of RAS inhibitors in terms of risk of mortality and severe/critical COVID-19 disease.